AB173302

Anti-C9 antibody [EPR11232-82]

RabMAb
Recombinant
What is this?

Be the first to review this product! Submit a review

(10 Publications)

Rabbit Recombinant Monoclonal C9 antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 10 publications.

View Alternative Names

Complement component C9, C9

4 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human colon tissue sections labeling Complement C9 with purified ab173302 at 1/10,000 dilution (0.07 μg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control : PBS instead of the primary antibody. Hematoxylin was used as a counterstain.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Immunohistochemical analysis of paraffin embedded Human spleen tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.

IHC-P

Supplier Data

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Immunohistochemical analysis of paraffin embedded Human colon tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.

Lab

Western blot - Anti-C9 antibody [EPR11232-82] (AB173302)

The molecular weight observed is consistent with what has been described in PMID : 29767720

All lanes:

Western blot - Anti-C9 antibody [EPR11232-82] (ab173302) at 1/10000 dilution

All lanes:

Human serum lysates at 15 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

Predicted band size: 63 kDa

Observed band size: 60-70 kDa

false

Carrier free

Anti-C9 antibody [EPR11232-82] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR11232-82

Isotype

IgG

Carrier free

Reacts with

Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/10000", "IHCP-species-notes": "For unpurified use at 1/100 - 1/200." }, "Mouse": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "For unpurified use at 1/100 - 1/200." }, "Rat": { "IP-species-checked": "notRecommended", "IP-species-dilution-info": "1/10 - 1/100", "IP-species-notes": "", "WB-species-checked": "notRecommended", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "", "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "For unpurified use at 1/100 - 1/200." } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

C9 also known as complement component 9 is a protein that plays an essential mechanical role in the complement system. It typically associates in the formation of the membrane attack complex (MAC). The C9 protein weighing around 71 kDa expresses in the liver and is secreted into the blood plasma. Alternative names like 'Cloud 9 capture' and 'C9 tag' often refer to research tools or motifs derived from the C9 protein rather than the protein itself. Researchers frequently study C9 in mouse models where its physiological roles can be explored.

Biological function summary

C9 participates in defending against pathogens. It joins other complement components like C5b C6 C7 and C8 to form the MAC complex which facilitates cell lysis by forming pores in the membrane of target cells. This action directly results in microbial cell destruction serving a critical immune function. C9 is not only part of the MAC complex but also holds significance due to its unique function as the last step in the formation of the pore influencing the efficacy of pathogen elimination.

Pathways

C9 functions primarily within the complement cascade which includes the classical and alternative pathways. Its role is in the terminal pathway segment that ultimately leads to the formation of the MAC and follows the activation of C5 which cleaves to produce C5b. This connection extends to proteins like C3 which is upstream in the cascade and significantly impacts the cascade's activation highlighting C9's function as an integral terminal component in these pathways.

Mutations or deficits in C9 relate to an increased susceptibility to infections particularly those caused by Neisseria species. This association results directly from its important role in the MAC formation. Additionally deficiency of C9 links to autoimmune disorders where the immune response may be improperly regulated due to compromised MAC formation. Other complement components like C6 and C8 may also relate to these diseases due to their collaboration with C9 in forming the MAC illustrating the interconnectedness of these proteins within the immune response framework.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Pore-forming component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed : 22832194, PubMed : 26841837, PubMed : 26841934, PubMed : 27052168, PubMed : 30552328, PubMed : 6177822, PubMed : 9212048, PubMed : 9634479). The MAC is initiated by proteolytic cleavage of C5 into complement C5b in response to the classical, alternative, lectin and GZMK complement pathways (PubMed : 39914456, PubMed : 39814882, PubMed : 9212048, PubMed : 9634479). The complement pathways consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed : 9212048, PubMed : 9634479). Constitutes the pore-forming subunit of the MAC complex : during MAC assembly, C9 associates with the C5b8 intermediate complex, and polymerizes to complete the pore (PubMed : 26841934, PubMed : 30111885, PubMed : 30552328, PubMed : 34752492, PubMed : 4055801, PubMed : 6177822).

See full target information C9

style

left-column

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

Viruses 16: PubMed39599800

2024

Complement Evasion Protects FCoV from Virus Clearance Within Prototypic FIP Lesions.

Applications

Unspecified application

Species

Unspecified reactive species

Anne Hönl,Sandra Felten,Katharina Erber,Michèle Bergmann,Sven Reese,Regina Hofmann-Lehmann,Marina L Meli,Andrea M Spiri,Katrin Hartmann,Kaspar Matiasek

Scientific reports 13:9902 PubMed37336938

2023

Successful targeting in situ of an oncogenic nuclear antigen by hapten induced tumor associated autoantibodies (iTAA).

Applications

Unspecified application

Species

Unspecified reactive species

Baofa Yu,Jian Zhang,Qiang Fu,Yan Han,Jie Zhang,Feng Gao,Peng Jing,Peicheng Zhang,Guoqin Zheng

Endocrine-related cancer 30: PubMed36951556

2023

Proteomic analysis of small intestinal neuroendocrine tumors and mesenteric fibrosis.

Applications

Unspecified application

Species

Unspecified reactive species

Anela Blažević,Anand M Iyer,Marie-Louise F van Velthuysen,Johannes Hofland,Gaston J H Franssen,Richard A Feelders,Marina Zajec,Theo M Luider,Wouter W de Herder,Leo J Hofland

Clinical proteomics 20:15 PubMed37024778

2023

Label-free quantitative proteomics reveals aberrant expression levels of LRG, C9, FN, A1AT and AGP1 in the plasma of patients with colorectal cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Chris Verathamjamras,Juthamard Chantaraamporn,Thiwaree Sornprachum,Photsathorn Mutapat,Daranee Chokchaichamnankit,Kanokwan Mingkwan,Virat Luevisadpibul,Chantragan Srisomsap,Somchai Chutipongtanate,Jisnuson Svasti,Voraratt Champattanachai

Scientific reports 11:4658 PubMed33633132

2021

Solidified glomerulosclerosis, identified using single glomerular proteomics, predicts end-stage renal disease in Chinese patients with type 2 diabetes.

Applications

Unspecified application

Species

Unspecified reactive species

Lijun Zhao,Fang Liu,Lin Li,Junlin Zhang,Tingli Wang,Rui Zhang,Wei Zhang,Xiaoyan Yang,Xiaoxi Zeng,Yiting Wang,Yucheng Wu,Hao Yang,Shisheng Wang,Yi Zhong,Huan Xu,Shanshan Wang,Ruikun Guo,Honghong Ren,Lichuan Yang,Baihai Su,Jie Zhang,Nanwei Tong,Xin J Zhou,Mark E Cooper

Proteomes 8: PubMed32971853

2020

Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Juthamard Chantaraamporn,Voraratt Champattanachai,Amnart Khongmanee,Chris Verathamjamras,Naiyarat Prasongsook,Kanokwan Mingkwan,Virat Luevisadpibul,Somchai Chutipongtanate,Jisnuson Svasti

The American journal of pathology 190:2095-2110 PubMed32598882

2020

Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis.

Applications

Unspecified application

Species

Unspecified reactive species

Felice D'Agnillo,Xiaoyuan Zhang,Matthew C Williams

BMC cancer 19:201 PubMed30841875

2019

The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Zhao,Jun Wu,Feiteng Lu,Xuan Peng,Chenlin Liu,Nanjin Zhou,Muying Ying

ACS omega 4:1272-1280 PubMed30729226

2019

Glycoproteomic Profiling Provides Candidate Myocardial Infarction Predictors of Later Progression to Heart Failure.

Applications

Unspecified application

Species

Unspecified reactive species

Kristine Y Deleon-Pennell,Osasere K Ero,Yonggang Ma,Rugmani Padmanabhan Iyer,Elizabeth R Flynn,Ingrid Espinoza,Solomon K Musani,Ramachandran S Vasan,Michael E Hall,Ervin R Fox,Merry L Lindsey

Scientific reports 8:5052 PubMed29567995

2018

Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5.

Applications

Unspecified application

Species

Unspecified reactive species

Takahiro Tougan,Jyotheeswara R Edula,Eizo Takashima,Masayuki Morita,Miki Shinohara,Akira Shinohara,Takafumi Tsuboi,Toshihiro Horii

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-C9 antibody [EPR11232-82]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-C9 antibody [EPR11232-82] (AB173302)

Western blot - Anti-C9 antibody [EPR11232-82] (AB173302)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Complementary Products

Assay Kits

Primary Antibodies

Primary Antibodies

Primary Antibodies

Secondary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (10)

Product promise